# Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA

> **NCT02396212** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Systemic Juvenile Idiopathic Arthritis

## Interventions

- **BIOLOGICAL:** Canakinumab

## Key facts

- **NCT ID:** NCT02396212
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-07
- **Primary completion:** 2017-03-07
- **Final completion:** 2018-08-01
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2019-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02396212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02396212, "Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02396212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*